发明名称 |
MOLECULAR DIAGNOSTIC TEST FOR PREDICTING RESPONSE TO ANTI-ANGIOGENIC DRUGS AND PROGNOSIS OF CANCER |
摘要 |
Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers. |
申请公布号 |
US2017073761(A1) |
申请公布日期 |
2017.03.16 |
申请号 |
US201515116641 |
申请日期 |
2015.02.09 |
申请人 |
ALMAC DIAGNOSTICS LIMITED |
发明人 |
HARKIN Denis Paul;KENNEDY Richard;KEATING Katherine E.;MCCAVIGAN Andrena;HILL Laura A.;DEHARO Steve;DAVISON Timothy;PATTERSON Fionnuala;DONEGAN Sinead;JELLEMA Gera;GOURLEY Charlie |
分类号 |
C12Q1/68 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for selecting whether to administer an anti-angiogenic therapeutic agent to a subject, comprising:
measuring the expression level(s) of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression level(s) of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. |
地址 |
Craigavon GB |